Journal of Pharmaceutical Sciences - Elsevier

AUTHOR INFORMATION PACK 18 Aug 2022 www.elsevier.com/locate/jpsi 1

JOURNAL OF PHARMACEUTICAL SCIENCES

AUTHOR INFORMATION PACK

TABLE OF CONTENTS.

XXX.

• Description• Impact Factor• Abstracting and Indexing• Editorial Board• Guide for Authors

p.1p.1p.2p.2p.10

ISSN: 0022-3549

DESCRIPTION.

Journal of Pharmaceutical Sciences (www.jpharmsci.org)

Access here additional scientific content published in the Journal of Pharmaceutical Sciences including:"freely available" Dedicated Issues to "Giants in the Pharmaceutical Sciences"; "freely available"Special Issue on Pharmaceutical Biotechnology; "freely available" Virtual Issues on Featured Papers,Ebert Prize papers, Biowaiver Monographs, 10 Most Downloaded Papers in 2015, 10 Most Cited Papersin 2015 and Editors' Choices of the Papers containing the Most Original and Most Significant ScientificFindings; other Virtual Issues on Clinical Trials and Translational Medicine Commentaries, SpecialTopic Commentaries, Global Health papers, and Lessons Learned; and a Drug Delivery Clinical TrialsDatabase.

The Journal of Pharmaceutical Sciences will publish original research papers, original researchnotes, invited topical reviews (including Minireviews), and editorial commentary and news.The area of focus shall be concepts in basic pharmaceutical science and such topics aschemical processing of pharmaceuticals, including crystallization, lyophilization, chemical stability ofdrugs, pharmacokinetics, biopharmaceutics, pharmacodynamics, pro-drug developments, metabolicdisposition of bioactive agents, dosage form design, protein-peptide chemistry and biotechnologyspecifically as these relate to pharmaceutical technology, and targeted drug delivery.

IMPACT FACTOR.

2021: 3.784 © Clarivate Analytics Journal Citation Reports 2022

http://www.jpharmsci.org


ABSTRACTING AND INDEXING.

Academic Search (EBSCO)Biological AbstractsBIOSIS PreviewsProQuestReaxysCurrent Chemical ReactionsCurrent Contents - Life SciencesEmbaseGlobal HealthIowa Drug Information Service (IDIS)PubMed/MedlineInternational Pharmaceutical AbstractsJournal Citation Reports - Science EditionPubMed/MedlineCSA Neurosciences AbstractsProtozoological AbstractsReview of Medical and Veterinary MycologyScience Citation IndexScience Citation Index ExpandedScopusSIIC Data BasesSoybean Abstracts (Online Edition)Web of Science

EDITORIAL BOARD.

Editor-in-Chief

Kenneth L. Audus, The University of Kansas, Lawrence, Kansas, United States of America

Editors

Sathy V. Balu-Iyer, University at Buffalo, Buffalo, New York, United States of AmericaHarry G. Brittain, Center for Pharmaceutical Physics, Milford, New Jersey, United States of AmericaJohn F. Carpenter, University of Colorado, Denver, Colorado, United States of AmericaFerdinando Giordano, University of Parma, Parma, ItalyMichael J. Hageman, The University of Kansas, Lawrence, Kansas, United States of AmericaBruno C. Hancock, Pfizer Global Research and Development, Princeton, New Jersey, United States of AmericaFilippos Kesisoglou, Merck Research Laboratories West Point, Lansdale, Pennsylvania, United States of AmericaHanns-Christian Mahler, F Hoffmann-La Roche Ltd, Basel, SwitzerlandThomas Rades, University of Copenhagen Faculty of Health and Medical Sciences, København, DenmarkChristian Schöneich, The University of Kansas, Lawrence, Kansas, United States of AmericaTetsuya Terasaki, University of Eastern Finland School of Pharmacy, Kuopio, FinlandIjeoma F. Uchegbu, University College London, London, England, United Kingdom

Editorial Advisory Board Members

Anjali Agrawal, Bristol-Myers Squibb Co Summit, Summit, New Jersey, United States of AmericaShin-ichi Akanuma, University of Toyama, Toyama, JapanHidetaka Akita, Tohoku University Graduate School of Pharmaceutical Sciences Faculty of PharmaceuticalSciences, Sendai, JapanSreedhara Alavattam, Genentech Inc, South San Francisco, California, United States of AmericaCarmen Alvarez-Lorenzo, University of Santiago de Compostela, Santiago de Compostela, SpainFernando Alvarez-Nunez, Amgen Inc, Thousand Oaks, California, United States of AmericaGregory E. Amidon, University of Michigan, Ann Arbor, Michigan, United States of AmericaGuohua An, The University of Iowa, Iowa City, Iowa, United States of AmericaTom Anchordoquy, University of Colorado, Aurora, Colorado, United States of AmericaPieter Annaert, KU Leuven Department of Pharmaceutical and Pharmacological Sciences, Leuven, BelgiumRobert Arnold, Auburn University, Auburn, Alabama, United States of AmericaPaolo Arosio, ETH Zurich, Zurich, SwitzerlandPer Artursson, Uppsala University, Uppsala, SwedenMarianne Ashford, AstraZeneca UK Ltd Macclesfield, Macclesfield, United KingdomPatrick F. Augustijns, Katholieke Universiteit Leuven Farmacotechnologie en Biofarmacie, Leuven, BelgiumBruce J. Aungst, AUC Sciences, Newark, Delaware, United States of America


Alejandro Pedro Ayala, Federal University of Ceara, Fortaleza, Ceará, BrazilSteven Baertschi, Baertschi Consulting LLC, Carmel, Indiana, United States of AmericaJane Bai, Silver Spring, Maryland, United States of AmericaAnnette B. Bak, AstraZeneca R&D Gothenburg, Göteborg, SwedenJoseph P. Balthasar, University at Buffalo, Buffalo, New York, United States of AmericaJames G. Bann, Wichita State University, Wichita, Kansas, United States of AmericaArvind K. Bansal, National Institute of Pharmaceutical Education and Research Department of Pharmaceutics,Mohali, Punjab, IndiaJared S. Bee, MacroGenics Inc, Rockville, Maryland, United States of AmericaChristel Bergström, Uppsala University, Uppsala, SwedenCory Berkland, The University of Kansas, Lawrence, Kansas, United States of AmericaAkhilesh Bhambhani, Merck and Co Inc West Point, Doylestown, Pennsylvania, United States of AmericaBakul Bhatnagar, Pfizer Andover, Andover, Massachusetts, United States of AmericaMichael Blaber, Florida State University, Tallahassee, Florida, United States of AmericaJeffrey T. Blue, Merck Research Vaccines Division, West Point, Pennsylvania, United States of AmericaJoshua Siaw Boateng, University of Greenwich, London, United KingdomRobin H. Bogner, University of Connecticut, Storrs, Connecticut, United States of AmericaBen J. Boyd, Monash University, Clayton, Victoria, AustraliaBirger Brodin, University of Copenhagen, Copenhagen, DenmarkIra Shea Buckner, Duquesne University, Pittsburgh, Pennsylvania, United States of AmericaJames M. Butler, GlaxoSmithKline Plc, Brentford, United KingdomMino R. Caira, University of Cape Town, Cape Town, South AfricaShawn Cao, Amgen Inc, Thousand Oaks, California, United States of AmericaCarla M. Caramella, University of Pavia, Pavia, ItalyJennifer (Laurence) Chadwick, Bioanalytix Inc, Cambridge, Maine, United States of AmericaSayantan Chattoraj, GlaxoSmithKline USA, King of Prussia, Pennsylvania, United States of AmericaBodhisattwa Chaudhuri, University of Connecticut, Storrs, Connecticut, United States of AmericaXiaodong Chen, Bristol-Myers Squibb Co, Wallingford, Connecticut, United States of AmericaWei Cheng, University of Michigan, Ann Arbor, Michigan, United States of AmericaPo-Chang Chiang, Genentech Inc, South San Francisco, California, United States of AmericaMerry Christie, Voisin Consulting Life Sciences Cambridge, Cambridge, Massachusetts, United States of AmericaAdeola O. Coker, University of the Incarnate Word, San Antonio, Texas, United States of AmericaDuncan Craig, University College London School of Pharmacy, London, United KingdomSudip Das, Butler University, Indianapolis, Indiana, United States of AmericaTapan K. Das, Bristol-Myers Squibb, Lawrenceville, New Jersey, United States of AmericaRutesh Hemant Dave, Long Island University - Brooklyn Campus, New York, New York, United States of AmericaVivek S. Dave, St John Fisher College, Rochester, New York, United States of AmericaRoberto DePaz, Viela Bio, Gaithersburg, Maryland, United States of AmericaRukman De SilvaMelgardt De Villiers, University of Wisconsin-Madison, Madison, Wisconsin, United States of AmericaYoshiharu Deguchi, Teikyo University School of Pharmaceutical Sciences Graduate School of PharmaceuticalSciences, Itabashi-Ku, JapanNunzio Denora, University of Bari, Bari, ItalyJames C. DiNunzio, Merck and Co Inc Kenilworth, Rahway, New Jersey, United States of AmericaJennifer Dressman, Goethe University Frankfurt, Frankfurt am Main, GermanyChristine M. Dufes, University of Strathclyde, Glasgow, Scotland, United KingdomCarsten Ehrhardt, The University of Dublin Trinity College, Dublin, IrelandDavid P. Elder, Ware, United KingdomReza Esfandiary, AstraZeneca Medimmune, Gaithersburg, Maryland, United States of AmericaFrank M. Etzler, Lake Erie College of Osteopathic Medicine School of Pharmacy, Erie, Pennsylvania, UnitedStates of AmericaDavid Fissore, Polytechnic of Turin, Torino, ItalyVito Fodera, University of Copenhagen, Copenhagen, DenmarkCamilla Foged, University of Copenhagen, Copenhagen, DenmarkAnastasia Foppoli, University of Milan, Milan, ItalyAmber Fradkin, KBI Biopharma - Boulder, Boulder, Colorado, United States of AmericaWolfgang Friess, Ludwig Maximilians University Munich, Munich, GermanyRyoichi Fujiwara, University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States of AmericaJohn F. Gamble, Bristol-Myers Squibb Pharmaceuticals Ltd, Uxbridge, United KingdomSandri Giuseppina, University of Pavia, Pavia, ItalyDavid J. Goldfarb, Merck & Co Inc, Kenilworth, New Jersey, United States of AmericaIgor Gonda, Respidex LLC, Dennis, Massachusetts, United States of AmericaSarah Gordon, Liverpool John Moores University, Liverpool, United KingdomMonica Goss, Amgen Inc, Thousand Oaks, California, United States of AmericaHenrik Green, Linköping University, Linköping, SwedenRichard H. Guy, University of Bath Department of Pharmacy and Pharmacology, Bath, United KingdomDavid Harris, Merck and Co Inc Kenilworth, Rahway, New Jersey, United States of America


David J. Hauss, Regeneron Pharmaceuticals Inc, Tarrytown, New York, United States of AmericaDavid Hayes, International Solidarity of Scientists, Danbury, Connecticut, United States of AmericaXiaorong X. He, Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Connecticut, United States of AmericaYan He, Sanofi Genzyme Drug Discovery and Development, Waltham, Massachusetts, United States of AmericaPaul W. S. Heng, National University of Singapore Department of Pharmacy, Singapore, SingaporeAnothony J. Hickey, RTI International, Research Triangle Park, North Carolina, United States of AmericaKazutaka Higaki, Okayama University, Okayama, JapanRene Holm, Janssen Pharmaceutica NV, Beerse, BelgiumSarah Hook, University of Otago, Dunedin, New ZealandKen-ichi Hosoya, University of Toyama, Toyama, JapanMunir A. Hussain, Mah Pharma Consulting LLC, Belle Mead, New Jersey, USAKatsuhisa Inoue, Tokyo University of Pharmacy and Life Science School of Pharmacy Department ofBiopharmaceutics, Hachioji, JapanTatsuhiro Ishida, University of Tokushima, Tokushima, JapanAkiko Ishii-Watabe, National Institute of Health Sciences, Kawasaki, JapanKousei Ito, Chiba University, Chiba, JapanYasunori Iwao, University of Shizuoka, Shizuoka, JapanKen-ichi Izutsu, National Institute of Health Sciences, Kawasaki, JapanKevin C. Johnson, Intellipharm LLC, Niantic, Connecticut, United States of AmericaLaToya Jones Braun, Regis University, Denver, Colorado, United States of AmericaDavid S. Jones, Queen's University Belfast, Belfast, United KingdomMarisa K. Joubert, Amgen Inc, Thousand Oaks, California, United States of AmericaGerald B. Kasting, University of Cincinnati, Cincinnati, Ohio, United States of AmericaYukio Kato, Kanazawa, JapanBruce A. Kerwin, Just - Evotec Biologics Inc, Seattle, Washington, United States of AmericaVitaliy V. Khutoryanskiy, University of Reading, Reading, United KingdomSandra Klein, University of Greifswald, Greifswald, GermanyPeter Kleinebudde, Heinrich Heine University Düsseldorf Institute of Pharmaceutics and Biopharmaceutics,Düsseldorf, GermanyGregory T. Knipp, Purdue University, West Lafayette, Indiana, United States of AmericaKaoru Kobayashi, Chiba University, Chiba, JapanJanet G. Koe, Corvus Pharmaceuticals Inc, Burlingame, California, United States of AmericaYoshiyuki Kubo, Toyoma, JapanOzan Kumru, The University of Kansas, Lawrence, Kansas, United States of AmericaYurong Lai, Bristol-Myers Squibb Co, Wallingford, Connecticut, United States of AmericaWilliam J. Lambert, Module 3 Pharmaceutical Consulting, Incline Village, Nevada, United States of AmericaMargaret Sue Landis, Pfizer Global Research and Development Computational Sciences Center of Emphasis,Cambridge, Massachusetts, United States of AmericaMajella E. Lane, University College London School of Pharmacy, London, United KingdomRobert S. Langer, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of AmericaDevalina Law, AbbVie Inc, North Chicago, Illinois, United States of AmericaDavid Lechuga-Ballesteros, AstraZeneca Pharmaceuticals LP, San Diego, California, United States of AmericaWooin Lee, Seoul National University College of Medicine Department of Pharmacology, Seoul, South KoreaS. Kevin Li, University of Cincinnati, Cincinnati, Ohio, United States of AmericaWilna Liebenberg, North-West University, Potchefstroom, South AfricaThorsteinn Loftsson, University of Iceland Faculty of Pharmaceutical Sciences, Reykjavik, IcelandKazuya Maeda, Kitasato University, Tokyo, Minato-Ku, JapanKrishna Mallela, University of Colorado - Anschutz Medical Campus, Aurora, Colorado, United States of AmericaAmedeo Marini, University of Pavia, Pavia, ItalyAllexandra Maroni, University of Milan, Milan, ItalyPatrick J. Marsac, University of Kentucky, Lexington, Kentucky, United States of AmericaToru Maruyama, Kumamoto University, Kumamoto, JapanSatohiro Masuda, International University of Health and Welfare, Otawara, JapanMichael B. Maurin, Maurin Healthcare Consulting LLC, Wilmington, Delaware, United States of AmericaMark McAllister, Pfizer Ltd, Tadworth, United KingdomGary McGeorge, Bristol-Myers Squibb Co Research & Development New Brunswick, New Brunswick, New Jersey,United States of AmericaPatrick McNamara, University of Kentucky, Lexington, Kentucky, United States of AmericaNatalie Medlicott, University of Otago, Dunedin, New ZealandDanforth Miller, Novartis Pharmaceuticals, Burlingame, California, United States of AmericaJosé Ramón Moyano-Méndez, University of Seville, Sevilla, SpainAnette Müllertz, University of Copenhagen Faculty of Health and Medical Sciences, København, DenmarkEric J. Munson, Purdue University, West Lafayette, Indiana, United States of AmericaS. Narasimha Murthy, University of Mississippi Department of Biomolecular Sciences Division of Pharmacology,Jackson, Mississippi, United States of AmericaSteven L. Nail, Baxter Bloomington, Bloomington, Indiana, United States of AmericaMiki Nakajima, Kanazawa University, Kanazawa, Japan


Takeo Nakanishi, Takasaki University of Health and Welfare, Takasaki, JapanAshwini Nangia, University of Hyderabad, Hyderabad, IndiaAjit S. Narang, Genentech Inc, South San Francisco, California, United States of AmericaPadma NarayanLinda O. Narhi, Amgen Inc, Thousand Oaks, California, United States of AmericaMarino Nebuloni, University of Parma, Parma, ItalyAnn Newman, Seventh Street Development Group, Kure Beach, North Carolina, United States of AmericaJoseph A. Nicolazzo, Monash University, Parkville, Victoria, AustraliaTomohiro Nishimura, Keio University, Tokyo, JapanNoriko Ogawa, Aichi Gakuin University School of Pharmacy Graduate School of Pharmacy, Nagoya, JapanTakuo Ogihara, Takasaki University of Health and Welfare, Takasaki, JapanSatoshi Ohtake, Pfizer Inc Chesterfield BioTherapeutics Pharmaceutical Science, Chesterfield, Missouri, UnitedStates of AmericaSumio Ohtsuki, Kumamoto University, Kumamoto, JapanTomoyuki Okuda, Meijo University, Nagoya, JapanTakashi Okura, Teikyo University School of Pharmaceutical Sciences Graduate School of PharmaceuticalSciences, Itabashi-Ku, JapanTetsuya Ozeki, Nagoya City University, Nagoya, JapanJayanth Panyam, University of Minnesota Twin Cities, Minneapolis, Minnesota, United States of AmericaYvonne Perrie, Strathclyde Institute of Pharmacy and Biomedical Sciences, Glasgow, United KingdomChristopher J. H. Porter, Monash University, Parkville, Victoria, AustraliaWei Qi, Amgen Inc, Thousand Oaks, California, United States of AmericaRoger A. Rajewski, The University of Kansas, Lawrence, Kansas, United States of AmericaTheodore W. Randolph, University of Colorado Boulder, Boulder, Colorado, United States of AmericaJukka Rantanen, University of Copenhagen, Copenhagen, DenmarkSusan M. Reutzel-Edens, Eli Lilly and Company, Indianapolis, Indiana, United States of AmericaChristopher Roberts, University of Delaware, Newark, Delaware, United States of AmericaMark C. Rogge, Takeda Oncology, Cambridge, Massachusetts, United States of AmericaBrian R. Rohrs, Bausch and Lomb Rochester, Rochester, New York, United States of AmericaLarry Rosen, VenatoRx Pharmaceuticals Inc, Malvern, Pennsylvania, United States of AmericaAmy S. Rosenberg, Center for Drug Evaluation and Research Office of Testing and Research, Silver Spring,Maryland, United States of AmericaAlfred Rumondor, Merck and Co Inc Kenilworth, Rahway, New Jersey, United States of AmericaChristoph Saal, Merck KGaA, Darmstadt, GermanyYoshimichi Sai, Kanazawa University Hospital, Kanazawa, JapanKrishnan Sampathkumar, MacroGenics Inc, Rockville, Maryland, United States of AmericaAnna Schwendeman, University of Michigan, Ann Arbor, Michigan, United States of AmericaAbu T.M. Serajuddin, St John's University Department of Pharmaceutical Sciences, New York, New York, UnitedStates of AmericaTeruna J. Siahaan, The University of Kansas, Lawrence, Kansas, United States of AmericaSatish K. Singh, Moderna Therapeutics Inc, Cambridge, Massachusetts, United States of AmericaFabio Sonvico, University of Parma, Parma, ItalyPierre O. Souillac, Andover Innovative Medicines Institute, Andover, Massachusetts, United States of AmericaDavid Spencer, Ipsen Biopharm Limited, Wrexham, UKWilliam C. Stagner, Campbell University College of Pharmacy and Health Sciences, Buies Creek, North Carolina,United States of AmericaGregory A. Stephenson, Eli Lilly and Company, Indianapolis, Indiana, United States of AmericaClare Strachan, University of Helsinki, Helsinki, FinlandRobert M. Straubinger, University at Buffalo, Buffalo, New York, United States of AmericaRobert G. Strickley, Gilead Sciences Inc, Foster City, California, United States of AmericaYongchao Su, Merck and Co Inc Kenilworth, Rahway, New Jersey, United States of AmericaChangquan Calvin Sun, University of Minnesota Twin Cities, Minneapolis, Minnesota, United States of AmericaRaj G. Suryanarayanan, University of Minnesota Twin Cities, Minneapolis, Minnesota, United States of AmericaDavid R. Taft, Long Island University - Brooklyn Campus, New York, New York, United States of AmericaYun K. Tam, Sinoveda Canada Inc, Edmonton, Alberta, CanadaIkumi Tamai, Kanazawa University, Kanazawa, JapanLynne S. Taylor, Purdue University, West Lafayette, Indiana, United States of AmericaRavindra W. Tejwani, ACADIA Pharmaceuticals Inc, Monmouth Junction, New Jersey, United States of AmericaAllen C. Templeton, Merck Research Laboratories West Point, Lansdale, Pennsylvania, United States of AmericaMaya Thanou, King's College London, London, United KingdomFrank-Peter Theil, UCB Biopharma SPRL, Brussels, BelgiumMike Tobyn, Bristol-Myers Squibb Pharmaceuticals Ltd Pharmaceutical Research Institute, Wirral, UnitedKingdomMasatoshi Tomi, Keio University, Tokyo, JapanNatalie L. Trevaskis, Monash University Faculty of Pharmacy and Pharmaceutical Sciences, Parkville, AustraliaNicolas Tsapis, National Centre for Scientific Research, Paris FranceYasuo Uchida, Tohoku University, Sendai, Japan


Susumu Uchiyama, Osaka University, Osaka, JapanTakuya Usui, Tohoku University, Sendai, JapanMichiel Van Speybroeck, Ardena Group Ltd, Gent, BelgiumGuy Van den Mooter, KU Leuven Department of Pharmaceutical and Pharmacological Sciences, Leuven, BelgiumMichel Vert, University of Montpellier, Montpellier, FranceDavid B. Volkin, The University of Kansas, Lawrence, Kansas, United States of AmericaJan L. Wahlstrom, Amgen Inc., Seattle, Washington, United States of AmericaNicolas Warne, Pfizer Andover, Andover, Massachusetts, United States of AmericaMarco van de Weert, University of Copenhagen Faculty of Health and Medical Sciences, København, DenmarkAdrian C. Williams, University of Reading, Reading, United KingdomDesmond Williams, University of South Australia, Adelaide, South Australia, AustraliaGerhard Winter, Ludwig Maximilians University Munich, Munich, GermanyQingguo Xu, Virginia Commonwealth University, Richmond, Virginia, United States of AmericaSamuel H. Yalkowsky, The University of Arizona College of Pharmacy, Tucson, Arizona, United States of AmericaFumiyoshi Yamashita, Kyoto University Graduate School of Pharmaceutical Sciences Faculty of PharmaceuticalSciences, Sakyo-ku, Kyoto, JapanShinji H. Yamashita, Setsunan University, Osaka, JapanHiroshi Yamazaki, Showa Pharmaceutical University Department of Drug Metabolism and Pharmacokinetics,Tokyo, JapanMehran Yazdanian, Teva Pharmaceutical Industries Ltd, West Chester, Pennsylvania, United States of AmericaKouichi Yoshinari, University of Shizuoka, Shizuoka, JapanHiroaki Yuasa, Nagoya City University, Nagoya, JapanJ. Axel Zeitler, University of Cambridge, Cambridge, United KingdomLucia Zema, University of Milan, Milan, ItalyGaylen M. Zentner, Comprehensive CMC Outsourcing LLC, Salt Lake City, Utah, United States of AmericaMing Zhang, University at Buffalo, Buffalo, New York, United States of AmericaQi (Tony） Zhou, Purdue University Department of Industrial and Physical Pharmacy, West Lafayette, Indiana,United States of AmericaHitoshi Sasaki, Nagasaki University, Nagasaki, Japan

Scientific Advisors to the Editors

Aktham Aburub, Eli Lilly and Company, Indianapolis, Indiana, United States of AmericaVivek Agrahari, CONRAD, Eastern Virginia Medical School (EVMS), Arlington, Virginia, United States of AmericaEmmanuel Akala, Howard University, Washington, District of Columbia, United States of AmericaIlgaz Akseli, Bristol-Myers Squibb, Lawrenceville, New Jersey, United States of AmericaWafa Al-Jamal, Queen's University Belfast, Belfast, United KingdomHassan Almoazen, The University of Tennessee Health Science Center, Memphis, Tennessee, United States ofAmericaLeah Appel, Green Ridge Consulting, Bend, Oregon, United States of AmericaKapildev Arora, Pfizer Inc, New York, New York, United States of AmericaAlex Avdeef, in-ADME Research, New York, New York, United States of AmericaJohn D. Ayres, Pharma Safety Solutions, LLC, Noblesville, Indiana, United States of AmericaRagna Berthelsen, University of Copenhagen, Copenhagen, DenmarkRajni Miglani Bhardwaj, Eli Lilly and Company, Indianapolis, Indiana, United States of AmericaSai H.S. Boddu, Ajman University, Ajman, United Arab EmiratesVera Brinks, ProQR Therapeutics NV, Leiden, NetherlandsChad Brown, Merck & Co Inc, Kenilworth, New Jersey, United States of AmericaNicole Buist, Merck and Co Inc Kenilworth, Rahway, New Jersey, United States of AmericaTing Cai, China Pharmaceutical University, Nanjing, ChinaWenjin Cao, ATARA BIOTHERAPEUTICS, Thousand Oaks, California, United States of AmericaStephen M. Carl, Bristol Myers Squibb Co, Princeton New Jersey, United States of AmericaMatteo Cerea, University of Milan, Milan, ItalyEmel Oyku Cetin Uyanikgil, Ege University, İzmir, TurkeyDavid Chalmers, Monash University, Clayton, Victoria, AustraliaSagnik Chatterjee, Syngene International Ltd, Bangalore, IndiaHarsh Chauhan, Creighton University, Omaha, Nebraska, United States of AmericaXin Chen, GlaxoSmithKline USA, King of Prussia, Pennsylvania, United States of AmericaJason K. Cheung, Merck & Co Inc, Kenilworth, New Jersey, United States of AmericaYite Robert Chou, Kite Pharma Inc, Santa Monica, California, United States of AmericaAviva Shing Fung Chow, The University of Hong Kong, Pok Fu Lam, Hong KongKwok Chow, Covar Pharmaceuticals, Mississauga, Ontario, CanadaJohn Chung, Amgen Inc, Thousand Oaks, California, United States of AmericaMichael DeHart, Carolina Medical Products Co, Farmville, North Carolina, United States of AmericaTahnee J. Dening, The University of Kansas, Lawrence, Kansas, United States of AmericaSathish Dharani, Texas A&M University, College Station, Texas, United States of AmericaNicholas Dickenson, Utah State University, Logan, Utah, United States of AmericaJin Dong, Simulations Plus Inc, Lancaster, California, United States of America


Rohit P. Dugar, Nutrilite Health Institute, Buena Park, California, United States of AmericaHala M. Fadda, Butler University, Indianapolis, Indiana, United States of AmericaSarinj Fattah, Royal College of Surgeons in Ireland, Dublin, IrelandShaoxin Feng, Allergan Irvine, Irvine, California, United States of AmericaAna Patricia Ferreira, Bristol-Myers Squibb Pharmaceuticals Ltd Pharmaceutical Research Institute, Wirral,United KingdomKimberly Foster, Bristol Myers Squibb Co, Princeton, New Jersey, United States of AmericaYuchuan Gong, AbbVie Inc, North Chicago, Illinois, United States of AmericaEric M. Gorman, Gilead Sciences Inc, Foster City, California, United States of AmericaFrancesca Greco, University of Reading, Reading, United KingdomHolger Grohganz, University of Copenhagen, Copenhagen, DenmarkManish Gupta, GlaxoSmithKline Plc, Brentford, United KingdomAndrea Hawe, Coriolis Pharma Research GmbH, Martinsried, GermanyHisamitsu Hayashi, The University of Tokyo, Tokyo, JapanDavid Hayes, International Solidarity of Scientists, Danbury, Connecticut, United States of AmericaAndrea Heinz, University of Copenhagen, Copenhagen, DenmarkGeoffrey Hird, Liquidia Corporation Inc, Research Triangle Park, North Carolina, United States of AmericaYu Ishima, University of Tokushima, Tokushima, JapanNazrul Islam, Queensland University of Technology, Brisbane, Queensland, AustraliaYijia Jiang, Coherus BioSciences Inc, Redwood City, California, United States of AmericaLiang Jin, Monash University, Clayton, Victoria, AustraliaVijay Joguparthi, Incilia Therapeutics Pvt Ltd, Hyderabad, IndiaNate H. Joh, Amgen Inc, Thousand Oaks, California, United States of AmericaJanan Jona, Genentech Inc, Bagdad, Kentucky, United States of AmericaMouhannad Jumaa, Astura Therapeutics, San Jose, California, United States of AmericaLeonid Kagan, Rutgers University Department of Pharmaceutics, Piscataway, New Jersey, United States ofAmericaCavan Kalonia, AstraZeneca Medimmune, Gaithersburg, Maryland, United States of AmericaTimothy J. Kamerzell, HCA Midwest Health System, Kansas City, Missouri, United States of AmericaToshiya Katsura, Ritsumeikan University, Kyoto, JapanJeffrey Michael Katz, AbbVie Inc, North Chicago, Illinois, United States of AmericaJanneke Keemink, Roche Products Ltd, Welwyn Garden City, United KingdomUmesh Kestur, Bristol-Myers Squibb Co Research & Development New Brunswick, New Brunswick, New Jersey,United States of AmericaDaniel Jon Kirby, Aston University, Birmingham, United KingdomKlaus Knop, Heinrich Heine University Düsseldorf, Dusseldorf, GermanyLakshmi Prajanna Kolluru, Medefil Inc, Glendale Heights, Illinois, United States of AmericaMary Krause, Bristol-Myers Squibb Co Research & Development New Brunswick, New Brunswick, New Jersey,United States of AmericaJeffrey P. Krise, The University of Kansas, Lawrence, Kansas, United States of AmericaLisa A. Kueltzo, National Institutes of Health, Bethesda, Maryland, United States of AmericaMartin Thomas Kuentz, Muttenz, SwitzerlandChris Kulczar, Merck & Co Inc, Kenilworth, New Jersey, United States of AmericaPrashant Kumar, The University of Kansas, Lawrence, Kansas, United States of AmericaElizabeth C. Kwong, Kwong Eureka Solutions, Kirkland, Quebec, CanadaRiikka Laitinen, University of Eastern Finland School of Pharmacy, Kuopio, FinlandYung-Chi Lee, Merck and Co Inc Kenilworth, Summit, New Jersey, United States of AmericaShui Yee Sharon Leung, The Chinese University of Hong Kong, Shatin, New Territories, Hong KongFeng Li, Baylor College of Medicine, Houston, Texas, United States of AmericaZ. Jane Li, Pharmaron Beijing Co Ltd, Beijing, ChinaXiangmin Liao, Himed, Old Bethpage, New York, United States of AmericaYu-Wei Lin, Monash University, Clayton, Victoria, AustraliaSachin Lohani, Merck & Co Inc - Rahway, Rahway, New Jersey, United States of AmericaAntonio Lopalco, University of Bari, Bari, ItalyEnxian Lu, Auson Pharmaceuticals, Piscataway, New Jersey, United States of AmericaQun Lu, Bristol-Myers Squibb, Berkley Heights, New Jersey, New Jersey, United States of AmericaSweta Manthena, Pfizer Inc, New York, New York, United States of AmericaChen Mao, Genentech Inc, South San Francisco, California, United States of AmericaWilliam A. Marinaro, Merck and Co Inc Kenilworth, Rahway, New Jersey, United States of AmericaIvan Marziano, Pfizer Global Research and Development Sandwich, Sandwich, United KingdomTakeshi Masuda, Kumamoto University, Kumamoto, JapanRoman Mathaes, Lonza Group Ltd, Basel, SwitzerlandCraig McKelvey, Merck and Co Inc Kenilworth, Rahway, New Jersey, United States of AmericaTim Menzen, Coriolis Pharma, Martinsried, GermanySaikishore Meruva, The University of Iowa, Iowa City, Iowa, United States of AmericaJeffrey W. Millard, PharMolecular, LLC, Bellingham, Washington, United States of AmericaMichael Morgen, Bend Research Inc., Bend, Oregon, United States of America


John Morrison, Bristol-Myers Squibb, Lawrenceville, New Jersey, United States of AmericaQingxin Mu, University of Washington, Seattle, Washington, United States of AmericaKarthik Nagapudi, Genentech Inc, South San Francisco, California, United States of AmericaSeshadri Neervannan, Allergan Irvine, Irvine, California, United States of AmericaHaichen Nie, Teva Pharmaceutical Industries Ltd, West Chester, Pennsylvania, United States of AmericaSaki Noguchi, Keio University, Tokyo, JapanDefang Ouyang, University of Macau, Taipa, MacaoLuka Palugan, University of Milan, Milan, ItalyGautam Pangu, Merck Sharp & Dohme UK Ltd, London, United KingdomYijun Pangu, Monash University, Clayton, Victoria, AustraliaJames Patterson, GlaxoSmithKline Australia Pty Ltd Abbotsford Office, Abbotsford, AustraliaBhushan S. Pattni, PureTech Health, Boston, Massachusetts, United States of AmericaAmrit Paudel, Graz University of Technology, Graz, AustriaShubhajit Paul, Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Connecticut, United States of AmericaSathyanarayana R. Perumalla, Seven Star Pharmaceutical Services, Wilmington, Delaware, United States ofAmericaAdam Todd Procopio, Merck & Co Inc, Kenilworth, New Jersey, United States of AmericaChetan Pujara, Allergan Irvine, Irvine, California, United States of AmericaRadha Ramakrishnan, Bristol-Myers Squibb, Lawrenceville, New Jersey, United States of AmericaYingqing Ran, Genentech Inc, South San Francisco, California, United States of AmericaJarkko Rautio, University of Eastern Finland School of Pharmacy, Kuopio, FinlandGregory A. Sacha, Baxter Healthcare Corp Round Lake, Round Lake, Illinois, United States of AmericaHideyuki Saito, Kumamoto University Hospital, Kumamoto, JapanAtul Saluja, Bristol-Myers Squibb, Framingham, Massachusetts, United States of AmericaBipul Sarma, Department of Chemical Sciences, Tezpur University, Tezpur, IndiaStephan Schmidt, University of Florida College of Pharmacy, Gainesville, Florida, United States of AmericaJay A. Schrier, Bioserv Corporation, San Diego, California, United States of AmericaChristian Seiler, ViiV Healthcare, Brentford, United KingdomJohn G. Sheehan, Merck Animal Health Rahway, Rahway, New Jersey, United States of AmericaAhmad Y. Sheikh, AbbVie Inc, North Chicago, Illinois, United States of AmericaJie Shen, University of Rhode Island - College of Pharmacy, Kingston, Rhode Island, United States of AmericaLimin Shi, Upsher-Smith Laboratories Inc, Maple Grove, Minnesota, United States of AmericaRoman Shimanovich, Amgen Inc, Thousand Oaks, California, United States of AmericaRok Sibanc, Bayer AG, Leverkusen, GermanyJürgen Siepmann, University of Lille Faculty of Pharmacy, Lille cedex, FranceDmitri Simberg, University of Colorado Cancer Center, Aurora, Colorado, United States of AmericaNataša Škalko-Basnet, UiT The Arctic University of Norway, Tromsø, NorwayWilliam Smith, Merck and Co Inc West Point, West Point, Pennsylvania, United States of AmericaPhillip Snyder, Vertex Pharmaceuticals Incorporated, Boston, Massachusetts, United States of AmericaIm-Sook Song, Kyungpook National University, Daegu, South KoreaAlejandro Sosnik, Technion Israel Institute of Technology, Haifa, IsraelTomas Sou, Uppsala University, Uppsala, SwedenTappei Takada, The University of Tokyo Hospital, Bunkyo-Ku, JapanYuma Tega, Teikyo University, Itabashi-Ku, JapanTomohiro Terada, Shiga University of Medical Science Hospital Pharmacy, Otsu, Shiga Prefecture, JapanMarc Tesconi, Pfizer Global Research and Development, Princeton, New Jersey, United States of AmericaDavid S. Thiriot, Merck & Co Inc, Kenilworth, New Jersey, United States of AmericaPrajwal G. Thool, Bristol-Myers Squibb, Lawrenceville, New Jersey, United States of AmericaFrancesco Trotta, University of Turin, Torino, ItalyRuhi Ubale, Grail Inc, Redwood City, California, United States of AmericaCarlo Vecchio, Pharmaceutical Technologies, Revislate, ItalyMaria Vertzoni, National and Kapodistrian University of Athens, Athens, GreeceValvanera Vozmediano, University of Central Florida, Orlando, Florida, United States of AmericaMatthias Wacker, Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Aachen, GermanyPaul Walsh, Merck and Co Inc Kenilworth, Rahway, New Jersey, United States of AmericaChenguang Wang, University of Minnesota Twin Cities, Minneapolis, Minnesota, United States of AmericaMichael Zhuo Wang, The University of Kansas, Lawrence, Kansas, United States of AmericaBaojian Wu, Guangzhou University of Chinese Medicine, Guangzhou, ChinaKe Wu, Allergan Irvine, Irvine, California, United States of AmericaTian Wu, Amgen Inc, Thousand Oaks, California, United States of AmericaLong Xu, Janssen Pharmaceuticals Research and Development Center Shanghai, Shanghai, ChinaYan Xu, Janssen Research and Development Spring House, Spring House, Pennsylvania, ChinaRajbharan Yadav, Genentech Inc, South San Francisco, California, United States of AmericaYoon Yeo, Purdue University Department of Industrial and Physical Pharmacy, West Lafayette, Indiana, UnitedStates of AmericaShawn. X. Yin, Bristol-Myers Squibb Co Research & Development New Brunswick, New Brunswick, New Jersey,United States of America


Etsuo Yonemochi, Hoshi University Graduate School of Pharmaceutical Sciences, Shinagawa-Ku, JapanXiaoda Yuan, Allergan Irvine, Irvine, California, United States of AmericaLi Zhang, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of AmericaXinyuan ZhangXiaobin (Ben) Zhao, The WhiteOak Group LLC, Washington, District of Columbia, United States of AmericaDeliang Zhou, AbbVie Inc, North Chicago, Illinois, United States of AmericaLei Zhu, Merck & Co Inc, Kenilworth, New Jersey, United States of America

Editor Emeritus

Ronald T. Borchardt, The University of Kansas, Lawrence, United States of America


GUIDE FOR AUTHORS.

INTRODUCTIONScopeJPharmSci focuses on two major questions of importance to pharmaceutical scientists: (i) Whatare the physical and biological barriers that limit the access of drugs to their therapeutic targets?;and (ii) How can drugs, excipients, traditional formulations, novel drug delivery systems and drugproducts be designed to maximize therapeutic efficacy? Answers to these questions have in the pastand will in the future be forthcoming from research in a variety of scientific disciplines includingbut not limited to the following: physical pharmacy; pharmaceutics; pharmaceutical technology;drug delivery; pharmaceutical engineering; materials science; nanotechnology; animal, human,cellular and molecular biopharmaceutics; animal and human pharmacokinetics, pharmacodynamicsand pharmacogenomics; drug metabolism and transport; biotechnology; medical chemistry, includingdrug design and prodrug strategies; biophysical chemistry; analytical and bioanalytical chemistry;physical organic, organic, and computational chemistry; molecular modeling; immunology;biochemistry; and cell and molecular biology. The scientific content of manuscripts submitted toJPharmSci should fit into one of the following subject categories:

Drug Discovery-Development InterfaceManuscripts in this scientific category should include descriptions of quantitative and mechanisticresearch in pharmaceutics, biopharmaceutics, pharmacokinetics, pharmacodynamics and drugmetabolism and transport that are normally conducted during the discovery of organic chemistry-based and biotechnology-based hits, leads and potential drug candidates. Research results ofparticular interest to the readers of JPharmSci would include those that afford valuable, newinformation about how a molecule's in vitro and in vivo behavior are influenced by its molecularand physico-chemical properties, traditional formulations and novel delivery systems used in leadoptimization studies. This scientific category would also encompass manuscripts that describe:(i) new and novel analytical methodologies and that would facilitate and/or more accurately andcompletely characterize the physico-chemical and biological properties of hits, leads and potentialdrug candidates; and (ii) new and novel formulations strategies and drug delivery systems, includingthose built on bio-and nanotechnologies, that would enhance the delivery of these molecules to theirpharmacological targets in animal models.

Pharmaceutical BiotechnologyManuscripts in this scientific category should include descriptions of quantitative and mechanisticresearch in pharmaceutics, drug delivery and pharmaceutical technology that are normally conductedduring the preclinical and clinical drug development of biotechnology-based drug candidates and drugs(e.g. peptides, proteins, antibodies, vaccines, DNA, RNA). Research results of particular interest tothe readers of JPharmSci would include those that afford valuable, new information about how amolecule's in vitro and in vivo behavior is influenced by its molecular and physico-chemical properties,traditional formulations and novel drug delivery systems used in preclinical and clinical studies and themanufacturing processes that give rise to the final drug product. This scientific category would alsoencompass manuscripts that describe: (i) new and novel analytical methodologies that would facilitateand/or more accurately and completely characterize the physico-chemical and biological propertiesof biotechnology-based drug candidates and drugs; and (ii) new and novel formulations strategiesand drug delivery systems, including those built on bio-and nanotechnologies, that would enhancethe delivery of these types of molecules to their pharmacological targets in animals and humans.

Pharmaceutics, Drug Delivery and Pharmaceutical TechnologyManuscripts in this scientific category should include descriptions of quantitative and mechanisticresearch in pharmaceutics, drug delivery and pharmaceutical technology that are normally conductedduring the preclinical and clinical development of organic chemistry-based drugs based drugs ordrug candidates. Research results of particular interest to the readers of JPharmSci would includethose that afford valuable, new information about how the in vitro and in vivo behavior of a drugmolecule or formulation excipient is influenced by its molecular and physico-chemical properties,traditional formulations and novel drug delivery systems used in pre-clinical and clinical studies andthe manufacturing processes that give rise to the final drug product. This scientific category alsoencompasses manuscripts that describe: (i) new and novel analytical methodologies that facilitateand/or more accurately and completely characterize physico-chemical and biological propertiesof biotechnology-based drugs and drug candidates; (ii) new and novel pro-drug strategies andformulation strategies and drug delivery systems, including those built on bio- and nanotechnologies,


that enhance the delivery of these types of molecules to their pharmacological targets in animals andhumans; and (iii) new and novel developments in manufacturing of drugs and drug delivery systems,including continuous manufacturing and the Quality by Design concept.

Pharmaceutical NanotechnologyManuscripts in this scientific category should describe quantitative and mechanistic experimentalor theoretical research in nanoscale-based pharmaceuticals or diagnostics in which the innovationresides specifically in the nanoscale aspects of the work. Manuscripts reporting advances inpharmaceutical nanotechnology that are being disclosed for the first time would be of particularinterest. Suitable topics in this category include advances in the fabrication of nanoscale materialswith demonstrably new or significant functionality potential for pharmaceutical applications. Additionaltopics include improved quantitative methods of characterization of nanoscale pharmaceuticalmaterials and mechanistic studies that contribute to an improved understanding of functionalityof nanoscale-based technologies with clear therapeutic implications. The manuscript's conclusionsshould be supported by relevant in vitro and/or in vivo experimental data and appropriatestatistical analysis. Notable exceptions to the requirement for appropriate physical and biologicalcharacterization are: (i) comprehensive and complete theoretical or computational studies; and (ii)meta-analyses of historical data or reviews of the existing literature.

Pharmacokinetics, Pharmacodynamics and Drug Transport and MetabolismManuscripts in this scientific category should encompass quantitative and mechanistic researchnormally conducted during the preclinical and clinical drug development of organic chemistry-based or biotechnology-based drug candidates or drugs that affords valuable, new information(e.g. drug-drug interactions) about the molecule's in vitro metabolism and/or in vitro absorption,distribution, metabolism and excretion (ADME) and how these properties relate to the molecule'sin vivo pharmacological and toxicological properties. This scientific category would also encompassmanuscripts that describe new and novel analytical methodologies that would facilitate and/ormore accurately and completely characterize the pharmacokinetics, pharmacodynamic and drugmetabolism and transport properties of these types of drug candidates and drugs in animals andhumans.

Global HealthManuscripts in this scientific category should encompass descriptions of quantitative andmechanistic research in pharmaceutics, biopharmaceutics, pharmacokinetics, pharmacodynamics,and metabolism and transport properties that are normally conducted during the discovery oforganic chemistry-based and biotechnology-based hits, leads and potential drug candidates and thepreclinical and clinical development of drug candidates and drugs targeting diseases common indeveloping countries. Research results of particular interest to the readers of JPharmSci would includethose that afford valuable, new information about how a molecule's in vitro and in vivo behaviorare influenced by its molecular and physico-chemical properties, traditional formulations, noveldrug delivery systems and manufacturing processes. The scientific category would also encompassmanuscripts that describe new and novel analytical methodologies that would facilitate and/or moreaccurately and completely characterize the pharmaceutics, pharmacokinetics, pharmacodynamics,drug metabolism, drug delivery and manufacturing properties of these types of drug candidates anddrugs in animals and humans.

Special Topic ClusterManuscripts in this category are part of an invited group of manuscripts that may be of multipletypes including reviews, minireviews, research articles, notes, commentaries, perspectives, lessonslearned, and/or workshop reports all focused on a specific research area or subject of general interestto pharmaceutical scientists. The topics and manuscripts contributed to this category are limited toinvitation only and initiated by approvals from the Editors and Editor-in-Chief.

Types of articleTypes of articleThe Editor-in-Chief and one Editor, as well as members of the Journal's Editorial Advisory Board andindependent experts, will review most manuscripts submitted to JPharmSci. However, the Editor-in-Chief and the Editors reserve the right to reject a manuscript without conducting an in-depth reviewif they feel that the manuscript is "out of scope" or it does not meet the minimal acceptance criteriafor publication in JPharmSci.


Rapid Communications are limited accounts of significant and original experimental and/ortheoretical results that fit within the scope of JPharmSci. The results must be of good quality andsignificance, originality, general interest and are determined by Reviewers and/or the Editor to beof urgent importance to the research area to justify accelerated publication. Authors are asked towrite their manuscripts in a clear and concise manner and to include only data crucial to arriving attheir final conclusions. Preferably manuscripts should not exceed 2,000 words of text and a total of4 figures and/or tables. Extra experimental and/or theoretical data in the form of figures and tablesshould be deposited under Supporting Information.

Research Articles are comprehensive accounts of significant and original experimental and/ortheoretical results that fit within the scope of JPharmSci. Authors are asked to write their manuscriptsin a clear and concise manner and to include only data crucial to arriving at their final conclusions.Preferably manuscripts should not exceed 5,500 words of text and a total of 8 figures and/or tables.Extra experimental and/or theoretical data in the form of figures and tables should be deposited underSupporting Information.

Notes differ from Rapid Communications in that they are final reports and from Research Articles inthat they are limited in scope. Authors are asked to write their manuscripts in a clear and concisemanner and to include only data crucial to arriving at their final conclusions. Preferably manuscriptsshould not exceed 2,000 words of text and a total of 4 figures and/or tables. Extra experimental and/ortheoretical data in the form of figures and tables should be deposited under Supporting Information.

Lessons Learned are articles which provide authors with a means of informing other scientists aboutcritical issues, experiences and observations, the descriptions of which would not be appropriate fora typical Research Article, Communication, Note, Commentary or Review. Examples include, but arenot limited to, key insights into an unanticipated manufacturing problem, knowledge accumulatedover a career of "tricks of the trade" for a given analytical or formulation method, how to avoid amistake that is repeated over and over again by scientists in industry and academia. Each articlewill be reviewed directly by an Editor who has expertise in the relevant scientific area. Because eachof these articles represents the personal opinion, experience and/or insights of the author(s), dataare not required (but could be described) nor does the identity of a given drug need to be divulged.Articles may contain several key references.

General Commentaries, Global Health Commentaries, and Special Topic Commentaries (byinvitation only) present authors' considered opinions on scientific or technical subjects within thescope of JPharm Sci. If the Commentary is critical of the content of a Research Article, Note, orRapid Communication published in the JPharmSci, the authors of the original article will be giventhe opportunity to submit a "reply" Commentary and the "critical" Commentary and the "reply"Commentary will be published back-to-back in the same issue of JPharmSci. Authors interested inpreparing Commentaries for JPharmSci should provide a brief outline to Editor John Carpenter.

Perspectives (by invitation only) articles summarize the viewpoints of distinguished pharmaceuticalscientists with regard to the current status and future direction of the field. Perspectives are similar inlength to Commentaries and Reviews, and may be submitted only by invitation. An author interestedin preparing a Perspective for JPharmSci should provide a brief outline to Professor John Carpenterrequesting an invitation to submit a manuscript in this category.

Reviews (by invitation only) provide a comprehensive summary of broadly-based topics of generalinterest to pharmaceutical scientists. Reviews are not limited as to the number of words, tables, figuresand references that may be included. An author interested in preparing a Review for JPharmSci shouldprovide a brief outline to Professor John Carpenter requesting an invitation to submit a manuscriptin this category.

Backstory Commentaries (by invitation only) provide a comprehensive historical style narrativeof an academic or industrial scientist's drug, prodrug, and formulation/excipient discovery ordevelopment story. Backstory Commentaries are not limited as to the number of words, tables, figuresand references that may be included. An author interested in preparing a Backstory Commentaryfor JPharmSci should provide a brief outline to Professor John Carpenter requesting an invitation tosubmit a manuscript in this category.


Minireviews (by invitation only) are well-focused, well-documented examinations of timely issuesin the pharmaceutical sciences. The issues may be of a controversial nature, or may address amore narrowly focused area than those typically covered in a Review. Minireviews are limited toapproximately 3,000-4,000 words, including tables, figures and references. An author interestedin preparing a Minireview for JPharmSci should provide a brief outline to Professor John Carpenterrequesting an invitation to submit a manuscript in this category.

Errata. If errors of consequence are found in the published paper, a correction of the error should besent by the author to the Editor-in-Chief for publication in the journal's Errata Section.

Submission checklistYou can use this list to carry out a final check of your submission before you send it to the journal forreview. Please check the relevant section in this Guide for Authors for more details.

Ensure that the following items are present:

One author has been designated as the corresponding author with contact details:• E-mail address• Full postal address

All necessary files have been uploaded:Manuscript:• Include keywords• All figures (include relevant captions)• All tables (including titles, description, footnotes)• Ensure all figure and table citations in the text match the files provided• Indicate clearly if color should be used for any figures in printGraphical Abstracts / Highlights files (where applicable)Supplemental files (where applicable)

Further considerations• Manuscript has been 'spell checked' and 'grammar checked'• All references mentioned in the Reference List are cited in the text, and vice versa• Permission has been obtained for use of copyrighted material from other sources (including theInternet)• A competing interests statement is provided, even if the authors have no competing interests todeclare• Journal policies detailed in this guide have been reviewed• Referee suggestions and contact details provided, based on journal requirements

For further information, visit our Support Center.

BEFORE YOU BEGINAll submitted manuscripts should contain previously unpublished original research.Submitted manuscripts should not be under consideration for publication elsewhere.

Ethics in publishingPlease see our information on Ethics in publishing.

Declaration of interestAll authors must disclose any financial and personal relationships with other people or organizationsthat could inappropriately influence (bias) their work. Examples of potential competing interestsinclude employment, consultancies, stock ownership, honoraria, paid expert testimony, patentapplications/registrations, and grants or other funding. Authors must disclose any interests in twoplaces: 1. A summary declaration of interest statement in the title page file (if double anonymized) orthe manuscript file (if single anonymized). If there are no interests to declare then please state this:'Declarations of interest: none'. 2. Detailed disclosures as part of a separate Declaration of Interestform, which forms part of the journal's official records. It is important for potential interests to bedeclared in both places and that the information matches. More information.

https://service.elsevier.com/app/home/supporthub/publishing/

https://www.elsevier.com/about/policies/publishing-ethics#Authors

https://service.elsevier.com/app/answers/detail/a_id/286/supporthub/publishing/


Submission declarationSubmission of an article implies that the work described has not been published previously (except inthe form of an abstract, a published lecture or academic thesis, see 'Multiple, redundant or concurrentpublication' for more information), that it is not under consideration for publication elsewhere, thatits publication is approved by all authors and tacitly or explicitly by the responsible authorities wherethe work was carried out, and that, if accepted, it will not be published elsewhere in the same form, inEnglish or in any other language, including electronically without the written consent of the copyright-holder.

Use of inclusive languageInclusive language acknowledges diversity, conveys respect to all people, is sensitive to differences,and promotes equal opportunities. Content should make no assumptions about the beliefs orcommitments of any reader; contain nothing which might imply that one individual is superior toanother on the grounds of age, gender, race, ethnicity, culture, sexual orientation, disability or healthcondition; and use inclusive language throughout. Authors should ensure that writing is free from bias,stereotypes, slang, reference to dominant culture and/or cultural assumptions. We advise to seekgender neutrality by using plural nouns ("clinicians, patients/clients") as default/wherever possibleto avoid using "he, she," or "he/she." We recommend avoiding the use of descriptors that referto personal attributes such as age, gender, race, ethnicity, culture, sexual orientation, disability orhealth condition unless they are relevant and valid. When coding terminology is used, we recommendto avoid offensive or exclusionary terms such as "master", "slave", "blacklist" and "whitelist". Wesuggest using alternatives that are more appropriate and (self-) explanatory such as "primary","secondary", "blocklist" and "allowlist". These guidelines are meant as a point of reference to helpidentify appropriate language but are by no means exhaustive or definitive.

Changes to authorshipAuthors are expected to consider carefully the list and order of authors before submitting theirmanuscript and provide the definitive list of authors at the time of the original submission. Anyaddition, deletion or rearrangement of author names in the authorship list should be made onlybefore the manuscript has been accepted and only if approved by the journal Editor. To request sucha change, the Editor must receive the following from the corresponding author: (a) the reasonfor the change in author list and (b) written confirmation (e-mail, letter) from all authors that theyagree with the addition, removal or rearrangement. In the case of addition or removal of authors,this includes confirmation from the author being added or removed.Only in exceptional circumstances will the Editor consider the addition, deletion or rearrangement ofauthors after the manuscript has been accepted. While the Editor considers the request, publicationof the manuscript will be suspended. If the manuscript has already been published in an online issue,any requests approved by the Editor will result in a corrigendum.

Language (usage and editing services)Please write your text in good English (American or British usage is accepted, but not a mixture ofthese). Authors who feel their English language manuscript may require editing to eliminate possiblegrammatical or spelling errors and to conform to correct scientific English may wish to use the EnglishLanguage Editing service available from Elsevier's Author Services.

Online Submission and Peer ReviewAuthors should ensure that papers conform to the scientific and style instructions given below. Inorder to expedite the publication process the Journal requires that manuscripts be submitted onlineat https://www.editorialmanager.com/xphs

Journal of Pharmaceutical Sciences has a completely digital submission, review, and productionprocess. We therefore ask for production-quality files at the time of submission of your manuscript.This will speed the production and distribution of your work across a variety of print and electronicplatforms. If you don't follow the simple guidelines given below, your submission will be returnedto you for additional revision. This will of course delay review and, in the event that your work isaccepted, would delay publication. Therefore we ask that you pay careful attention at this time andwe thank you for your cooperation.

If you have not already done so, create an account for yourself in the system at the submission site,https://www.editorialmanager.com/xphs by clicking on the "Register Now" button. Please follow on-screen instructions and the system will guide you through the submission process.



https://webshop.elsevier.com/language-editing-services/language-editing/

https://webshop.elsevier.com/language-editing-services/language-editing/


You are also able to exit/re-enter at any stage before finally "submitting" your work. All submissionsare kept strictly confidential. You may contact the Journal's Assistant Editor, Robert Dawdy [email protected] or tel. 636-293-9844.

CopyrightUpon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (seemore information on this). An e-mail will be sent to the corresponding author confirming receipt ofthe manuscript together with a 'Journal Publishing Agreement' form or a link to the online versionof this agreement.

Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internalcirculation within their institutions. Permission of the Publisher is required for resale or distributionoutside the institution and for all other derivative works, including compilations and translations. Ifexcerpts from other copyrighted works are included, the author(s) must obtain written permissionfrom the copyright owners and credit the source(s) in the article. Elsevier has preprinted forms foruse by authors in these cases.

Author rightsAs an author you (or your employer or institution) have certain rights to reuse your work. Moreinformation.

Elsevier supports responsible sharingFind out how you can share your research published in Elsevier journals.

Role of the funding sourceYou are requested to identify who provided financial support for the conduct of the research and/orpreparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; inthe collection, analysis and interpretation of data; in the writing of the report; and in the decision tosubmit the article for publication. If the funding source(s) had no such involvement, it is recommendedto state this.

Open accessPlease visit our Open Access page for more information.

SubmissionConfirmation of manuscript content must accompany initial submission. Manuscriptssubmitted to the Journal of Pharmaceutical Sciences should contain significant, unpublished andoriginal data not being considered simultaneously for publication elsewhere. All authors should beaware of and in agreement with the submission of this manuscript and share responsibility for itscontent. The manuscript should provide full and appropriate credit to those who contributed tothe underlying hypothesis and the generation and interpretation of the experimental data. Relatedresearch in the field should be acknowledged in the manuscript through appropriate literaturecitations. Manuscripts should be devoid of any forms of plagiarism with respect to ideas, data, words,graphic materials or other forms of communication. All authors should be aware that this manuscriptwill be checked for plagiarism using CrossCheck anti-plagiarism software.

Scientific Misconduct Issues. An alleged violation of any of these basic rules of scientific ethicswill be investigated confidentially in accord with the procedures set forth in the American MedicalAssociation Manual of Style: A guide for Authors and Editors (10th Edition). If the violations aredeemed to be sufficiently serious, the Editor-in-Chief will request that the authors provide a writtenexplanation. If the authors do not provide an explanation or the explanation is unsatisfactory, suchthat the Journal's Editorial Team believes that the evidence clearly shows that scientific misconductdid occur, the Editor-in-Chief would promptly reject the manuscript or proceed to retract a publishedmanuscript. In addition, the Editor-in-Chief reserves the right to notify the authors's institution for theviolation of the Journal's scientific ethics policy. The Editor-in-Chief also reserves the option to requestthe author's institution iniate a formal investigation into the alleged violation of scientific ethics andto report back to the Journal in a timely manner. If the formal institutional investigation confirmsscientific misconduct, the Editor-in-Chief will promptly reject a pending manuscript or proceed toretract a published manuscript. Further, JPharmSci Editorial Team reserves the right to impose punitiveactions (e.g. ban on publishing in the Journal) on authors proven to have violated any of the basicrules of scientific ethics.

https://www.elsevier.com/about/policies/copyright

https://www.elsevier.com/about/policies/copyright/permissions

https://www.elsevier.com/__data/assets/word_doc/0007/98656/Permission-Request-Form.docx



https://www.elsevier.com/authors/journal-authors/submit-your-paper/sharing-and-promoting-your-article

https://www.elsevier.com/journals/journal-of-pharmaceutical-sciences/0022-3549/open-access-options


PREPARATION(a) General Considerations. In order to expedite peer review, authors are required to submittheir manuscripts online at https://www.editorialmanager.com/xphs. (See Online Submission andPeer Review above for details about the online submission process.)

Authors should write manuscripts in clear, concise English. The responsibility for all aspects ofmanuscript preparation rests with the authors. Authors should note that extensive changes orrewriting of the manuscript will not be undertaken by the editors.

There are no page charges for publication in the Journal of Pharmaceutical Sciences.

(b) Suggested Reviewers. The Journal requires that submitting authors suggest at least fourreviewers, up to a maximum of six reviewers, two of which must be Editorial Advisory Board (EAB)members; one must be a Scientific Advisor. Please include suggested reviewers' contact information.A list of Editorial Advisory Board (EAB) members and a list of Scientific Advisors can be found byclicking on the corresponding link.

Editorial Advisory Board Members Keywords List

Scientific Advisors Keywords List

Conflicts of Interest: Reviewers. Reviewers should not evaluate a manuscript authored or co-authored by a person with whom the reviewer has personal or professional relationships that mightbias their judgment of the manuscript's scientific merits. Reviewers should be sensitive to theappearance of potential conflicts of interest when the content of the manuscript relates directly to thereviewer's published or unpublished research. If in doubt, the reviewer should immediately notify theappropriate Editor and seek their advice on whether to proceed with the review. Reviewers should alsobe sensitive to the appearance of potential conflict of interest when the manuscript describes resultsfrom experiments using patented technologies, which are competitive with patented technologiesinvented by the reviewer or the reviewer's employer.

Article structureTextSubmit your text in DOC format (preferred font size: 10 pt Helvetica). Do not embed figures or tablesin this document. These should be submitted as separate files.

(c) Title. Titles are of great importance for current awareness and for information retrieval. Thewording of titles should be chosen carefully to provide information on the contents and to functionas "points of entry" for information retrieval. Symbols, formulas, or arbitrary abbreviations shouldnot be included in the title, except chemical symbols to indicate the structure of isotopically labeledcompounds.

(d) Abstract. The abstract should briefly (80-200 words) present, in one paragraph, the problem andexperimental approach and state the major findings and conclusions. It should be self-explanatoryand suitable for reproduction without rewriting. Footnotes or undefined abbreviations may not beused. If a reference must be cited, complete publication data must be given.

(e) Keywords. Please provide up to 10 keywords that reflect the scientific content of your manuscript.These keywords must come from the Journal's official keyword list. In addition to facilitating indexingof articles, our keyword system assists in the assignment of qualified reviewers for your manuscript.In addition, each member of our Editorial Advisory Board has selected keywords that are applicableto their own work.

(f) Abbreviations. Abbreviations are used without periods. Standard abbreviations should be usedthroughout the manuscript. All nonstandard abbreviations should be kept to a minimum and must bedefined in the text following their first use and in a footnote at the beginning of the manuscript.

https://www.elsevier.com/__data/promis_misc/2022 XPHS EAB Keywords2.pdf

https://www.elsevier.com/__data/promis_misc/2022_SAE_Keywords.pdf

https://www.elsevier.com/__data/promis_misc/JPSOfficialKeywords.pdf

https://www.elsevier.com/__data/promis_misc/XPHS2018_EAB_Keywords.pdf


(g) QSAR/QSPR. All manuscripts dealing with quantitative structure activity relationships (QSAR)and quantitative structure property relationships (QSPR) must identify individual chemical structuresusing Chemical Abstracts Service (CAS) SciFinder. To aid authors in the use of CAS SciFinder forstructure searching, please click here for a Commentary written by Dr. Christopher Lipinski describingthe procedure. This Commentary appears in Journal of Pharmaceutical Sciences 91(12):2470-2472.

(h) Experimental Section. The experimental procedures should be described in sufficient detail toenable others to repeat the experiments. Names of products and manufacturers [with city, state,and country (if other than the U.S.)] should be included only if alternate sources are deemedunsatisfactory. Brand names may be used only once in the manuscript. For subsequent designation,use "formulation A", product B", etc. Novel experimental procedures should be described in detail,but published procedures should merely be referred to by literature citation of both the original andany published modifications. The purity of key compounds and descriptions(s) of the method(s) usedto determine purity should be included in this section. For buffers, use terminology such as "20 mMpotassium phosphate buffer (pH 7.7) containing...". Also, state w/v or v/v when appropriate.

Identification of and precautions for handling hazardous chemicals and dangerous procedures shouldbe placed at the beginning of the section. An example would be "Caution: The following chemicals arehazardous and should be handled carefully; (list of chemicals and handling procedures or references)".

Manuscripts containing data generated from animal and/or human studies must specify the committeeand the institution that approved the experimental protocols used to generate these data.

(i) Results. The results should be presented concisely. Tables and figures should be designed tomaximize the presentation and comprehension of the experimental data. Attention should be paid tothe matter of significant figures (usually, no more than three). The same data should not be presentedin more than one figure or in both a figure and a table. As a rule, interpretation of the results shouldbe reserved for the discussion section of a Research Article, but under some circumstances it maybe desirable to combine results and discussion in a single section.

(j) Discussion. The purpose of the discussion is to interpret the results and to relate them to existingknowledge in the field in as clear and brief a fashion as possible. Information given elsewhere in themanuscript should not be repeated in the discussion. Extensive reviews of the literature should beavoided.

(k) References. Literature references must be numbered in one consecutive series by order ofmention in the text, with numbers as unparenthesized superscripts. The accuracy of the referencesis the responsibility of the author. The complete list of references should be typed double-spaced onseparate page(s) at the end of the manuscript and follow the format shown. All references shouldinclude titles.

For journals: Yoneto K, Li SK, Higuchi WI, Jiskoot W, Herron JN. Fluorescent probe studiesof the interactions of 1-alkyl-2-pyrrolidones with stratum corneum lipid liposomes. J Pharm Sci1996;85(5):511-517.

For edited books: Rall TW, Schleifer LS. Drugs effective in the therapy of the epilepsies. In: GilmanAG, Goodman LS, Rall TW, Murad F, eds. The Pharmacological Basis of Therapeutics, 7th ed., NewYork: Macmillan Publishing Co.; 1985:446-472.

For web references: Health Care Financing Administration. 1996 statistics at a glance. Available at:http://www. hcfa.gov/stats/stathili.htm. Accessed December 2, 1996.

As a minimum, the full URL should be given and the date when the reference was last accessed. Anyfurther information, if known (DOI, author names, dates, reference to a source publication, etc.),should also be given. Web references can be listed separately (e.g., after the reference list) under adifferent heading if desired, or can be included in the reference list.

For submitted manuscripts: List as "in press" only if formally accepted for publication; otherwise, use"unpublished results" after the names of authors.

(l) Supplementary material

https://www.elsevier.com/__data/promis_misc/JPSLipinski.pdf


Elsevier accepts electronic supplementary material to support and enhance your scientific research.Supplementary files offer the author additional possibilities to publish supporting applications, high-resolution images, background datasets, sound clips and more. Supplementary files supplied will bepublished online alongside the electronic version of your article in Elsevier Web products, includingScienceDirect: http://www.sciencedirect.com In order to ensure that your submitted material isdirectly usable, please provide the data in one of our recommended file formats. Authors shouldsubmit the material in electronic format together with the article and supply a concise and descriptivecaption for each file. For more detailed instructions please visit our artwork instruction pages athttps://www.elsevier.com/artworkinstructions. The Supplementary material format of this journal canaccommodate and make readily available almost any type of supplementary figures or data (e.g.,reproductions of spectra, experimental procedures, tabulated data, expanded discussion of peripheralfindings, etc.). The author should include a Supporting Information Available statement that describesthe material at the end of the printed manuscript text. Consult a current issue of the Journal forthe proper wording of this statement. Supporting Information should be clear and of high contrast(suitable for direct photoreproduction) and submitted in quadruplicate on 8.5- × 11-in. paper. Allpages of Supporting Information must be consecutively numbered. Captions or legends for figures,spectra, etc., must appear directly on the figure.

(m) Acknowledgments. This section should acknowledge financial support, technical assistance,advice from colleagues, gifts, etc. Permission must be received from persons whose contribution tothe work is acknowledged in the manuscript.

(n) Spectral Data. It may be desirable to include such data for representative compounds in aseries, for novel classes of compounds, and in structural determinations. Usually, it is not desirable toinclude routine spectral data for every compound in the manuscript. Papers where interpretations ofspectra are critical to structural elucidation and those in which band shape or fine structure needs tobe illustrated may be published with spectra included. When such presentations are deemed essential,only pertinent sections should be reproduced.

(o) Experimental Data. Experimental methods must be referenced or described in sufficient detailto permit the experiments to be repeated by others. Detailed descriptions of experimental methodsshould be placed in the experimental procedures section. Data may be presented as numericalexpressions in tables or in graphical form with no duplication of information in the text. If tables orfigures include a minimal number of experimental values (< four), the data should be presented inthe text. Units should be abbreviated without punctuation and with no distinction between singularand plural forms (e.g., 1 mg, 25 mg).If possible, statistical significance of the experimental datashould be provided. Statistical probability ( p ) in tables, figures, figure legends and text shouldbe expressed as * p < 0.05, ** p < 0.01, and *** p < 0.001. For multiple comparisons within atable, footnotes italicized in lower case, superscript letters should be used and defined in the tablelegend. References to statistical methods of calculation should be provided. If statistical limits cannotbe provided, the number of determinations and some indication of the variability and reliability ofthe results should be provided. For animal experimental data, doses and concentrations should beexpressed as molar quantities (e.g., mmol/kg, mM) when comparisons are made between compoundshaving large differences in molecular weights. The routes of administration of test compounds andvehicles used should be indicated. For animal and human studies, authors must specify thecommittee and the institution that approved the experimental protocols used to generatethese data.

Formatting of funding sourcesList funding sources in this standard way to facilitate compliance to funder's requirements:

Funding: This work was supported by the National Institutes of Health [grant numbers xxxx, yyyy];the Bill & Melinda Gates Foundation, Seattle, WA [grant number zzzz]; and the United States Institutesof Peace [grant number aaaa].

It is not necessary to include detailed descriptions on the program or type of grants and awards. Whenfunding is from a block grant or other resources available to a university, college, or other researchinstitution, submit the name of the institute or organization that provided the funding.

If no funding has been provided for the research, it is recommended to include the following sentence:


This research did not receive any specific grant from funding agencies in the public, commercial, ornot-for-profit sectors.

If experimental data on proprietary compounds (i.e. compounds whose chemical structures are notavailable in the public domain) and/or using proprietary procedures (i.e. experimantal proceduresand/or components of procedures that are not described in the public domain) are provided in amanuscript, authors should carefully read the next two paragraphs.

Traditionally, scientific papers must reveal sufficient information for the work to be repeated by others.That tradition led to the policy that JPharmSci has applied to manuscripts that contain information onproprietary small molecules. This policy essentially states that information pertaining to proprietary(small molecule) compounds can be published providing that, in the opinion of the reviewers andeditors, the paper would be publishable based solely on the information derived from studies of knowncompounds. Thus, information on proprietary compounds has been considered to be supplementalwhile the decision to publish or not has relied on compounds for which structures were disclosed.

Studies of proprietary proteins and other biologicals pose a difficult situation for JPharmSci. In somecases, complete structures may not have been determined or, even if the structure is available,compounds having identical structures may be difficult for others to generate (e.g., the amino acidsequences of immunoglobulin hypervariable regions). Yet, interesting studies of proprietary biologicalscan nevertheless be envisioned that may be deemed to have sufficient value that the failure to revealdetailed structural information should not be a deterrent to publication. Therefore, the journal willdetermine the acceptability of such papers on an individual basis. Decisions of acceptability will bemade using the following criteria: (a) the structural information provided is adequate for the purposeof evaluating the paper using rigorous scientific standards; (b) the structural information provided issufficient to enable others to verify the results by conducting essentially the same experiments; and(c) the work is judged to be of sufficient importance that a lack of complete structural informationdoes not significantly detract from its scientific contributions.

(p) Tables. Tabulation of experimental results is encouraged when this leads to more effectivepresentation or to more economical use of space. Please submit tables as editable text and not asimages. Number tables consecutively in accordance with their appearance in the text and place anytable notes below the table body. Be sparing in the use of tables and ensure that the data presentedin them do not duplicate results described elsewhere in the article. Please avoid using vertical rules.Tables should be created with a word processor and saved in either DOC or RTF format. Do notembed tables in your text. Tables should be on separate pages and saved as one file in DOC format.Provide a brief title with each table and a brief heading for each column. Clearly indicate the unitsof measure (preferably SI). Data should be rounded to the nearest significant figure. Explanatorymaterial referring to the whole table is to be included as a footnote to the title (a). Footnotes in tablesshould be given lower case letter designations and cited in the tables as italicized superscripts. Tablesthat require special treatment, such as insertion of arrows or other special symbols under or overalphanumeric characters, or contain many structures should be submitted as camera-ready copy.

(q) Artwork. The quality of the illustrations printed in your paper depends on the quality of theoriginals you provide. Electronic submission of illustrations is required.

Electronic artworkGeneral points• Make sure you use uniform lettering and sizing of your original artwork.• Embed the used fonts if the application provides that option.• Aim to use the following fonts in your illustrations: Arial, Courier, Times New Roman, Symbol, oruse fonts that look similar.• Number the illustrations according to their sequence in the text.• Use a logical naming convention for your artwork files.• Provide captions to illustrations separately.• Size the illustrations close to the desired dimensions of the published version.• Submit each illustration as a separate file.• Ensure that color images are accessible to all, including those with impaired color vision.

A detailed guide on electronic artwork is available.You are urged to visit this site; some excerpts from the detailed information are given here.Formats

https://www.elsevier.com/authors/author-schemas/artwork-and-media-instructions


If your electronic artwork is created in a Microsoft Office application (Word, PowerPoint, Excel) thenplease supply 'as is' in the native document format.Regardless of the application used other than Microsoft Office, when your electronic artwork isfinalized, please 'Save as' or convert the images to one of the following formats (note the resolutionrequirements for line drawings, halftones, and line/halftone combinations given below):EPS (or PDF): Vector drawings, embed all used fonts.TIFF (or JPEG): Color or grayscale photographs (halftones), keep to a minimum of 300 dpi.TIFF (or JPEG): Bitmapped (pure black & white pixels) line drawings, keep to a minimum of 1000 dpi.TIFF (or JPEG): Combinations bitmapped line/half-tone (color or grayscale), keep to a minimum of500 dpi.Please do not:• Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); these typically have alow number of pixels and limited set of colors;• Supply files that are too low in resolution;• Submit graphics that are disproportionately large for the content.

For best results, submit illustrations in the actual size at which they should appear in thejournal. Original illustrations which do not need to be reduced to fit a single or double column willyield the best quality. Lettering should be no smaller than 6 points. (Helvetica type works well forlettering.) Lines should be no thinner than 0.5 point. Lettering and lines should be of uniform density.If you must submit artwork that must be reduced, use larger lettering and thicker lines so that, whenreduced, the artwork meets the above-mentioned parameters. Avoid using complex textures andshading to achieve a three-dimensional effect. To show a pattern, choose a simple cross-hatch design.

Color artwork. All color figures will be reproduced in full color in the online edition of the journal atno cost to the authors. Authors are encouraged to submit color illustrations that highlight the textand convey essential scientific information. For best reproduction, bright, clear colors should be used.Dark colors against a dark background do not reproduce well; please place your color images againsta white background whenever possible.

Color artworkPlease make sure that artwork files are in an acceptable format (TIFF (or JPEG), EPS (or PDF) orMS Office files) and with the correct resolution. If, together with your accepted article, you submitusable color figures then Elsevier will ensure, at no additional charge, that these figures will appear incolor online (e.g., ScienceDirect and other sites). Further information on the preparation of electronicartwork.

In addition to the above resolution guidelines, color figures must be submitted in a CMYK color. Donot submit color figures as RGB.

Illustration servicesElsevier's Author Services offers Illustration Services to authors preparing to submit a manuscript butconcerned about the quality of the images accompanying their article. Elsevier's expert illustratorscan produce scientific, technical and medical-style images, as well as a full range of charts, tablesand graphs. Image 'polishing' is also available, where our illustrators take your image(s) and improvethem to a professional standard. Please visit the website to find out more.

Chemical Structures. Structures should be produced with the use of a drawing program such asChemDraw. Authors using the current versions of ChemDraw, ChemIntosh, and ChemWindows willfind the necessary parameters incorporated into these programs ("JOC Document" under the Windowsmenus for ChemDraw and "Reduce 60% for JOC Style" under the Options menu for ChemIntosh/ChemWindows). In ChemDraw version 4.5, files should be saved in TIFF format to allow use ofelectronic files in production.

(r) Nomenclature. It is the responsibility of the authors to provide correct nomenclature. Allnomenclature must be consistent and unambiguous and should conform with current American usage.Insofar as possible, authors should use systematic names similar to those used by Chemical AbstractsService, the International Union of Pure and Applied Chemistry, and the International Union ofBiochemistry and Molecular Biology.

The chemical names for drugs should be used. If the terminology is unwieldy, nonproprietary namesof drugs may be used throughout the manuscript after the first mention and identification. Formallyadopted nonproprietary names listed in United States Adopted Names (USAN) should be used. In



https://webshop.elsevier.com/illustration-services/


cases in which a name has not been assigned by USAN, the International Nonproprietary Names(INN), approved by the World Health Organization, should be used. Trade names and laboratory codesshould not be used except as additional information.

(s) Analyses. Adequate evidence to establish identity and purity should be provided for newcompounds. When possible, this should include elemental analysis. The purity of compounds used forbiological testing should be stated with a description of the method used to evaluate it.

(t) Hazardous Materials. All hazardous chemicals should be clearly identified as such. Precautionsfor handling dangerous materials or for performing hazardous procedures should be explicitly statedand referenced.

Data referencesThis journal encourages you to cite underlying or relevant datasets in your manuscript by citing themin your text and including a data reference in your Reference List. Data references should include thefollowing elements: author name(s), dataset title, data repository, version (where available), year,and global persistent identifier. Add [dataset] immediately before the reference so we can properlyidentify it as a data reference. The [dataset] identifier will not appear in your published article.

Preprint referencesWhere a preprint has subsequently become available as a peer-reviewed publication, the formalpublication should be used as the reference. If there are preprints that are central to your work or thatcover crucial developments in the topic, but are not yet formally published, these may be referenced.Preprints should be clearly marked as such, for example by including the word preprint, or the nameof the preprint server, as part of the reference. The preprint DOI should also be provided.

AFTER ACCEPTANCEProofsOne set of page proofs (as PDF files) will be sent by e-mail to the corresponding author (if we do nothave an e-mail address then paper proofs will be sent by post) or a link will be provided in the e-mail so that authors can download the files themselves. To ensure a fast publication process of thearticle, we kindly ask authors to provide us with their proof corrections within two days. Elsevier nowprovides authors with PDF proofs which can be annotated; for this you will need to download the freeAdobe Reader, version 9 (or higher). Instructions on how to annotate PDF files will accompany theproofs (also given online). The exact system requirements are given at the Adobe site.If you do not wish to use the PDF annotations function, you may list the corrections (including repliesto the Query Form) and return them to Elsevier in an e-mail. Please list your corrections quoting linenumber. If, for any reason, this is not possible, then mark the corrections and any other comments(including replies to the Query Form) on a printout of your proof and scan the pages and return via e-mail. Please use this proof only for checking the typesetting, editing, completeness and correctnessof the text, tables and figures. Significant changes to the article as accepted for publication will onlybe considered at this stage with permission from the Editor. We will do everything possible to get yourarticle published quickly and accurately. It is important to ensure that all corrections are sent backto us in one communication: please check carefully before replying, as inclusion of any subsequentcorrections cannot be guaranteed. Proofreading is solely your responsibility.

Publication Online. Articles accepted for publication in the Journal of Pharmaceutical Sciences willbe posted as Articles in Press as soon as author corrections to proofs are received and incorporated.This can occur anywhere from 2 to 6 weeks well in advance of the cover date of the online issue.Authors should take this into account when planning their intellectual and patent activities relatedto an article. The actual date on which the article is posted online is recorded in a separate line inthe PDF of the article.

OffprintsThe corresponding author will, at no cost, receive a customized Share Link providing 50 days freeaccess to the final published version of the article on ScienceDirect. The Share Link can be used forsharing the article via any communication channel, including email and social media. For an extracharge, paper offprints can be ordered via the offprint order form which is sent once the article isaccepted for publication. Both corresponding and co-authors may order offprints at any time viaElsevier's Author Services. Corresponding authors who have published their article gold open accessdo not receive a Share Link as their final published version of the article is available open access onScienceDirect and can be shared through the article DOI link.

https://get.adobe.com/reader

https://get.adobe.com/reader

https://helpx.adobe.com/reader/system-requirements.html

https://www.elsevier.com/authors/journal-authors/submit-your-paper/sharing-and-promoting-your-article/share-link

https://www.sciencedirect.com/

https://webshop.elsevier.com/article-services/article-offprints/


AUTHOR INQUIRIESVisit the Elsevier Support Center to find the answers you need. Here you will find everything fromFrequently Asked Questions to ways to get in touch.You can also check the status of your submitted article or find out when your accepted article willbe published.

© Copyright 2018 Elsevier | https://www.elsevier.com

https://service.elsevier.com/app/home/supporthub/publishing

https://service.elsevier.com/app/answers/detail/a_id/29155/supporthub/publishing/kw/status+submitted+article/

https://service.elsevier.com/app/answers/detail/a_id/5981/kw/5981/p/13783/supporthub/publishing

https://service.elsevier.com/app/answers/detail/a_id/5981/kw/5981/p/13783/supporthub/publishing

Journal of Pharmaceutical Sciences - Elsevier

Documents